Phase II Study of Paclitaxel in Combination with Carboplatin in Patients With Stage IB-II Cervical Cancer.

Phase II Study of Paclitaxel in Combination with Carboplatin in Patients With Stage IB-II Cervical Cancer. - Phase II Study of TC in Patients With Cervical Cancer.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012400

Enrollment

Registered

2013-11-25

Start date

2010-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

Pacritaxel 175mg/m2 and Carboplatin AUC 5 iv. triweekly, 6 cycles

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. The case that it was judged that additional adjuvant therapy was necessary after radical hysterectomy for cervical cancer. 2.PS <2 3.Nuet >1500/mm3 4.Plt >100000/mm3

Exclusion criteria

Exclusion criteria: 1. within 6weeks after operation 2. active infection 3. the case witch doctor judged to be inappropriate

Design outcomes

Primary

Measure	Time frame
overall survival	—

Countries

Japan

Contacts

Public ContactMasanori Kanemura

Osaka medical college Obstetrics and Gynecology

gyn044@poh.osaka-med.ac.jp072-683-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026